With HER2 established as an actionable driver of advanced/metastatic non-small cell lung cancer (NSCLC), integrating HER2 testing and HER2-targeted tyrosine kinase inhibitors (TKIs) into clinical practice is essential for healthcare providers navigating today’s complex clinical landscape. This interactive Clinical Case Challenge tests your ability to apply emerging HER2-based treatment strategies in advanced/metastatic NSCLC. In this interactive Clinical Case Challenge, you will: Test your knowledge on the clinical evidence and guideline recommendations on the use of HER2-targeted TKIs in advanced/metastatic NSCLC, including biomarker testing Apply clinical reasoning to real-world patient scenarios to inform HER2-based regimen selection based on biomarker status, as well as toxicity management Receive immediate, evidence-based feedback to help refine decision-making in your own practice Gain insight on how your answers compare with your peers. Upon completion, you will receive a concise expert summary to support HER2 testing, personalized treatment selection, and toxicity management to improve patient care in advanced/metastatic NSCLC.
Credit & MOC Details
Credit information is provided by the course provider. We recommend confirming credit eligibility with the provider or your licensing board before starting the activity.
Credit types
MOC types
FDA REMS
Qualifies for MIPS
Target Specialties
Address:
- 360 Park Avenue South
Pricing
99% of listed courses are free
298 of a sample of 300 are free · 416 courses listed here.
Collected from the provider’s public pages
Specialties served/covered
- Addiction Medicine
- Adolescent Medicine
- Advanced Heart Failure & Transplant Cardiology
- Allergy & Clinical Immunology
- Anatomic & Clinical Pathology
- Cardiovascular Disease
- Communication & Shared Decision-Making
- Dermatology
- Endocrinology, Diabetes & Metabolism
- Family Medicine
- Gastroenterology
- Gastrointestinal Surgery
- General & Adult Psychiatry
- General Internal Medicine
- General Operative Anesthesia
- General Pediatrics
- General Surgery
- Geriatric Medicine
- Gynecologic Oncology
- Health Equity & Inclusion
- Hematology
- Hospital Medicine
- Infectious Disease
- Interventional Cardiology
- Interventional Radiology
- Medical Genetics & Genomics
- Medical Leadership & Administration
- Medical Oncology
- Metabolic & Bariatric Surgery
- Mood & Anxiety Disorders
- Musculoskeletal Oncology
- Nephrology
- Neurodevelopmental Disabilities
- Neurology
- Neuromuscular Medicine
- Nuclear Medicine
- Obstetrics & Gynecology
- Ophthalmology
- Pain Medicine
- Patient Education & Health Literacy
- Patient Safety & Quality Improvement
- Pediatric Hematology-Oncology
- Pediatric Neurology
- Practice Management & Ethics
- Pulmonary Disease
- Radiation Oncology
- Regional Anesthesia & Acute Pain
- Rheumatology
- Sleep Medicine
- Surgical Oncology
- Thoracic Surgery
- Transplant Hepatology
- Urological Oncology
- Urology
- Anesthesiology
- Cardio-Vascular
- Cross-Specialty
- GI & Liver
- Infectious Disease
- Internal Medicine
- Medical Subspecialties
- Neurology
- Ob/Gyn
- Oncology & Hematology
- Orthopedics
- Pain & Palliative
- Pathology & Lab
- Pediatrics
- Primary care
- Psychiatry
- Radiology
- Surgery
- Urology
- No reviews yet. Be the first to share yours.
Pricing
Free
Reported to ACCME by the provider
- Case study / clinical scenario
- Credit · Up to 0.5 credits
- Commercial Support
-
ReleasedJul 10, 2026
-
Last day to claim creditJul 10, 2027 9 months left
-
Answers in CME Inc. (AiCME) Beyond the Biomarker: Bridging Patient Voices and Precision Care in HER2-Mutant NSCLC
-
International Association for the Study of Lung Cancer Empowering Oncology Teams in HER2 Testing: Applying the New NCCN Standards to Transform NSCLC Care
-
AXIS Medical Education, Inc. HER2 in Solid Tumors: From Pathology to Personalized Treatment Plans
-
PRIME Education, Inc. (PRIME®) Optimizing HER2 Assessment and Treatment in Advanced NSCLC: From Guidelines to the Clinic
-
PRIME Education, Inc. (PRIME®) Targeting HER2 in NSCLC: Novel and Emerging Therapies and Practical Guidance
-
PRIME Education, Inc. (PRIME®) From Testing to Treatment: Navigating HER2-Testing and Clinical Evidence Across Solid Tumors
